Item no. |
HY-10195B-1mg |
Manufacturer |
MedChem Express
|
CASRN |
169939-93-9 |
Amount |
1 mg |
Quantity options |
100 mg
10mM*1 mL
10 mg
1 mg
25 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
99.84 |
Formula |
C28H29ClN4O3 |
Citations |
ACS Omega. 2020 Oct 12;5(41):26551-26561.<br/>Biosci Rep. 2018 Sep 7;38(5):BSR20171459.<br/>Cell Biosci. 2021 Feb 8;11(1):32.<br/>Diabetes Metab Syndr Obes. 2019 Nov 4;12:2289-2302.<br/>Endocrinology. 2018 May 1;159(5):2253-2263.<br/>Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.<br/>Acta Pharm Sin B. 2022.<br/>FASEB J. 2024 Mar 31;38(6):e23564.<br/>Trop J Pharm Res. 2022; 21(12): 2508.<br/>[1]Jirousek MR, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39(14):2664-2671.<br/>[2]Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-199.<br/>[3]Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1(6):929-35.<br/>[4]Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2702-6. |
Smiles |
O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O.[H]Cl |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
LY333531 (hydrochloride) |
Available |
|
Product Description |
Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
Metabolism-sugar/lipid metabolism |
MolecularWeight |
505.01 |
Clinical Information |
Launched |
Manufacturers Research Area |
Metabolic Disease |
Solubility |
DMSO : 6.67 mg/mL (ultrasonic) |
Target |
PKC |
Manufacturers Target |
PKC |
Isoform |
PKCα; PKCβ; PKCγ; PKCδ; PKCε; PKCη |
Manufacturers Pathway |
Epigenetics; TGF-beta/Smad |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.